{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:53:18Z","timestamp":1791546798419,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"DOI":"10.1007\/s40123-026-01499-7","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:11:02Z","timestamp":1791544262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study Design for ELARA, a Phase 3b Trial of Aflibercept 8\u00a0mg in Previously Treated Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-5766","authenticated-orcid":false,"given":"David M.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson J.","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenchieh","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"1499_CR1","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e60."},{"issue":"6","key":"1499_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1159\/000519518","volume":"244","author":"C Barresi","year":"2021","unstructured":"Barresi C, Borrelli E, Fantaguzzi F, Grosso D, Sacconi R, Bandello F, et al. Complications associated with worse visual outcomes in patients with exudative neovascular age-related macular degeneration. Ophthalmologica. 2021;244(6):512\u201322.","journal-title":"Ophthalmologica"},{"issue":"7","key":"1499_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375\u201394.","journal-title":"Ophthalmology"},{"key":"1499_CR4","doi-asserted-by":"crossref","unstructured":"Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463\u20137.","DOI":"10.1074\/jbc.274.33.23463"},{"issue":"2","key":"1499_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS, Cheung N, Simo R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1499_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","volume":"244","author":"R Flores","year":"2021","unstructured":"Flores R, Carneiro A, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021;244(6):495\u2013511.","journal-title":"Ophthalmologica"},{"issue":"4","key":"1499_CR7","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda GA, Bailey ST, Kim SJ, Kovach JL, Lim JI, Ying GS, et al. Age-related macular degeneration preferred practice pattern\u00ae. Ophthalmology. 2025;132(4):P1\u201374.","journal-title":"Ophthalmology"},{"issue":"4","key":"1499_CR8","doi-asserted-by":"publisher","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","volume":"132","author":"JI Lim","year":"2025","unstructured":"Lim JI, Kim SJ, Bailey ST, Kovach JL, Vemulakonda GA, Ying GS, et al. Diabetic retinopathy preferred practice pattern\u00ae. Ophthalmology. 2025;132(4):P75\u2013162.","journal-title":"Ophthalmology"},{"issue":"10432","key":"1499_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"10432","key":"1499_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"4","key":"1499_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801.","journal-title":"Ophthalmology"},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2147\/OPTH.S205147","volume":"15","author":"LT Phan","year":"2021","unstructured":"Phan LT, Broadhead GK, Hong TH, Chang AA. Predictors of visual acuity after treatment of neovascular age-related macular degeneration - current perspectives. Clin Ophthalmol. 2021;15:3351\u201367.","journal-title":"Clin Ophthalmol"},{"key":"1499_CR13","doi-asserted-by":"crossref","unstructured":"Chaudhary V, Retina Evidence and Trials INternational Alliance (R.E.T.I.N.A.) Study Group. The need for a pragmatic, individualized treat-and-extend (T&E) treatment paradigm for centre-involving diabetic macular oedema. Eye (Lond). 2023;37(12):2431\u20133.","DOI":"10.1038\/s41433-023-02455-6"},{"issue":"1","key":"1499_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2026;133(1):39\u201350.","journal-title":"Ophthalmology"},{"issue":"5","key":"1499_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ophtha.2025.10.028","volume":"133","author":"DV Do","year":"2026","unstructured":"Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, et al. Intravitreal aflibercept 8 mg for diabetic macular edema: ninety-six-week results from the randomized phase 2\/3 PHOTON trial. Ophthalmology. 2026;133(5):577\u201388.","journal-title":"Ophthalmology"},{"key":"1499_CR16","unstructured":"Sivaprasad S, Korobelnik JF. BCVA gains with aflibercept 8 mg maintained through week 96 in PULSAR with extended treatment intervals in patients with nAMD. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 5\u20139, 2024; Seattle, WA."},{"key":"1499_CR17","unstructured":"Do DV. Aflibercept 8 mg for diabetic macular edema: 96-week results from the phase 2\/3 PHOTON trial. Presented at: Angiogenesis, Exudation, and Degeneration Annual Meeting; February 3, 2024; Virtual."},{"issue":"2-a Suppl","key":"1499_CR18","first-page":"S3","volume":"24","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24(2-a Suppl):S3\u201315.","journal-title":"J Manag Care Spec Pharm"},{"key":"1499_CR19","unstructured":"Brown DM, Turner KC, Bihorel S, Chiu J, Harnisch L, Chittendon J, et al. Population pharmacokinetic and exposure-response analyses for aflibercept. Presented at: American Society of Retina Specialists Annual Meeting; July 17\u201320, 2024; Stockholm, Sweden."},{"key":"1499_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-026-04588-w","author":"DM Brown","year":"2026","unstructured":"Brown DM, Berliner AJ, Rao R. Infographic: study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema. Eye (Lond). 2026. https:\/\/doi.org\/10.1038\/s41433-026-04588-w.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1499_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"10326","key":"1499_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"key":"1499_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"issue":"10326","key":"1499_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"4","key":"1499_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.oret.2024.12.021","volume":"9","author":"MA Zarbin","year":"2025","unstructured":"Zarbin MA, Weng CY, London NJS, Koh AHC, Gallego-Pinazo R, Chaudhary V, et al. Disease activity criteria impact dosing interval assignment in neovascular age-related macular degeneration trials. Ophthalmol Retina. 2025;9(4):404\u20137.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"1499_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40123-025-01108-z","volume":"14","author":"B Bhatia","year":"2025","unstructured":"Bhatia B, Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Selvam S, et al. The impact of disease activity criteria on extending injection intervals in real-world patients with neovascular age-related macular degeneration. Ophthalmol Ther. 2025;14(4):773\u201386.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1499_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3341\/kjo.2020.0109","volume":"35","author":"O Ugurtay","year":"2021","unstructured":"Ugurtay O, Kockar A, Sengul EA. Real-life data of treat-and-extend intravitreal ranibizumab and aflibercept therapy in wet age-related macular degeneration patients: 3-year results. Korean J Ophthalmol. 2021;35(4):280\u20136.","journal-title":"Korean J Ophthalmol"},{"issue":"12","key":"1499_CR28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond). 2020;34(12):2249\u201356.","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01499-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:11:06Z","timestamp":1791544266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01499-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":28,"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01499-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David M. Brown has received consulting fees\/honoraria for ongoing services provided as a consultant for AAVantgarde, AbbVie, Alpha Insights, AmerisourceBergen, Annexon, Apellis, Bayer, Biogen, Biotissue, BMC, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Curacle, Eyconis, Eyebiotech, Glaukos, Harrow, HCPLive, Impact Education, Innovate Retina, Kodiak Sciences, Kowa, Lumanity, Medscape, Merit, Multimedia Medical, Neurotech, Novartis Pharma AG, Ocular Therapeutix, Ocuphire, Optos, PER, Regeneron Pharmaceuticals, Inc., RetinAI, Medical AG, RMEI, Samsung Bioepis, Senju Pharmaceutical, SIMR Biotech, Snell Medical, Stealth BioTherapeutics, Thea, Topcon, Voiant, WebMD, Xequel Bio, and Xfacto; has received ongoing research support as a principal investigator for trials sponsored by 4D Molecular Therapeutics, AffaMed Therapeutics, Alcon, Alexion, Amgen, Annexon, Apellis, Ashvattha Therapeutics, Astellas, Bayer, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, EyePoint, F. Hoffmann-La Roche, Genentech, Glaukos, Graybug Vision, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, Janssen, Jaeb Center for Health Research (Diabetic Retinopathy Clinical Research Network), Kodiak Sciences, Kyoto Drug Discovery & Development Co., Ltd., Kyowa Kirin, LumiThera, MeiraGTx, Mylan, National Eye Institute\/National Institutes of Health, Neuracle Genetics, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Ollin Biosciences, Opthea, Optos, Outlook Therapeutics, Oxular, Regeneron Pharmaceuticals, Inc., Rezolute, Sandoz, Senju Pharmaceutical, Shanghai Henlius Biotech, Stealth BioTherapeutics, Xbrane, and Zeiss Meditec; has disclosed a patent for Optos; and has stock options with Adverum, Clearside Biomedical, and Ocuphire. Rohini Rao, Disha Patel, Yenchieh Cheng, and Zhanying Bai are employees and stakeholders of Regeneron Pharmaceuticals, Inc. Alyson J. Berliner is a former employee of Regeneron Pharmaceuticals, Inc. Charles C. Wykoff is a consultant for and has received research support from 4D Molecular Therapeutics, AbbVie,\u00a0Adverum, Alcon, Bayer, Boehringer Ingelheim, Clearside Biomedical, EyePoint, Genentech, Janssen, Kodiak Sciences, Merck, Novartis, Opthea, Regeneron Pharmaceuticals, Inc., REGENXBIO, and Roche.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial adhered to the ethical guidelines of the Declaration of Helsinki and the International Council for Harmonisation E6 Guideline for Good Clinical Practice, and applicable laws and regulations. An institutional review board (Advarra; Columbia, MD) approved the study protocol (\n                      Approval#: Pro00079569)\n                      . Written informed consent was provided by each participant before trial enrollment.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}